Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...
Google-backed, AI-developed drugs are headed to trial by 2026, DeepMind CEO says
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
FiercePharma3d
Lilly, Merck team with Purdue University to pioneer new drug production methods
Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...
STAT13d
Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund
Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Swissinfo2d
DeepMind’s Hassabis Sees AI-Designed Drug Trials This Year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this ...
FierceBiotech13d
Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund
Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...
STAT10d
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal
Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...
Yahoo9d
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Here's What History Has to Say. Billionaire Investor Bill Ackman Just Went All In On One of His Favorite Stocks: He Plans to Hold It "Forever" AI Agents Are Coming in 2025. Here's My Top Stock ...